Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Position Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 1.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 823,222 shares of the medical technology company’s stock after purchasing an additional 15,577 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.58% of Alphatec worth $4,577,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Point72 Asset Management L.P. lifted its holdings in shares of Alphatec by 65.2% during the second quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock valued at $33,365,000 after purchasing an additional 1,260,137 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after acquiring an additional 297,850 shares during the last quarter. Fred Alger Management LLC increased its holdings in shares of Alphatec by 0.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,638,303 shares of the medical technology company’s stock valued at $27,570,000 after acquiring an additional 21,078 shares during the last quarter. First Turn Management LLC increased its holdings in shares of Alphatec by 37.3% during the 2nd quarter. First Turn Management LLC now owns 1,360,410 shares of the medical technology company’s stock valued at $14,216,000 after acquiring an additional 369,792 shares during the last quarter. Finally, Royce & Associates LP boosted its stake in Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after purchasing an additional 165,954 shares during the period. Institutional investors own 66.35% of the company’s stock.

Alphatec Price Performance

NASDAQ:ATEC opened at $9.62 on Friday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock’s 50-day simple moving average is $7.98 and its 200 day simple moving average is $8.15. The company has a market cap of $1.36 billion, a P/E ratio of -7.52 and a beta of 1.38. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ATEC. Lake Street Capital reduced their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Finally, Barclays lifted their target price on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.